OncoTracker Appoints James Kuo as CEO
WEST HOLLYWOOD, Calif., Aug. 20, 2018 /PRNewswire/ — OncoTracker, Inc. announced the appointment of James Kuo, MD, MBA, as its Chief Executive Officer. Dr. Kuo is a biotech executive with more than 20 years of experience in corporate development, finance and licensing.
Previously, Dr. Kuo served as Managing Director at Athena Bioventures. In addition, he has been Chairman and CEO at Synthetic Biologics and BioMicro Systems. Earlier in his career, he was Managing Director at HealthCare Ventures and Associate Director of Corporate Licensing and Development at Pfizer. He currently serves as Board Chairman at ImmunoPrecise Antibodies and Monarch Labs. Dr. Kuo received his medical degree from the University of Pennsylvania, and his MBA from the Wharton School of Business. His undergraduate degree in molecular biology is from Haverford College.
“We are excited to have someone of James’ breadth of experience lead our company,” stated James R. Berenson, MD, OncoTracker’s founder and Board Chairman. “His strategy to expand through multiple licensing deals, increasing biomarker testing revenues, and driving clinical diagnostics and therapeutic development fits with our board’s stated goals.”
“I actively sought out this role because I believe OncoTracker has the potential to become a major biotech company,” said Dr. Kuo. “While the initial focus will be on building a profitable business in the rapidly growing multiple myeloma market, we intend to serve a broader cancer population by integrating novel immune therapies with companion diagnostics.”
OncoTracker, Inc. is a West Hollywood-based oncology company with exclusive rights to a novel blood biomarker that is the target of several multiple myeloma therapies in clinical development. OncoTracker utilizes this biomarker to monitor the tumor burden and predict the therapeutic outcome of multiple myeloma patients. In addition, OncoTracker believes this biomarker has clinical relevancy in chronic lymphocytic leukemia, B-cell lymphoma and potentially other solid cancers. OncoTracker further possesses intellectual property related to two multiple myeloma therapies, one of which is in clinical trials.